Figure 6. SRF inhibitor-CCG-1423 improves glucose tolerance in vivo.
(A) Glucose tolerance improved following in vivo CCG-1423 treatment in HFD-fed mice (HFD+CCG) compared with vehicle-treated HFD or chow-fed controls. (B) Area under curve for glucose tolerance test. **P < 0.01 for HFD vs. HFD-CCG AUC. (C) Insulin levels at 30 minutes after glucose injection are significantly reduced in CCG-1423–treated mice. *P < 0.05.